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A B S T R A C T
Purpose: We conducted a systematic review and meta-analysis to evaluate the eﬃcacy of diﬀerent treatment for
Demodex blepharitis. Parameters studied were mites count, improvement of symptoms and mites’ eradication,
stratiﬁed on type of treatments and mode of delivery of treatments (local or systemic).
Method: The PubMed, Cochrane Library, Embase, ClinicalTrials.gov, Google scholar and Science Direct data-
bases were searched for studies reporting an eﬃcacy of treatments for Demodex blepharitis.
Results: We included 19 studies (14 observational and 5 randomized clinical trials), for a total of 934 patients,
1741 eyes, and 13 diﬀerent treatments. For mites count, eradication rate, and symptoms improvement, meta-
analysis included ﬁfteen, fourteen and thirteen studies, respectively. The overall eﬀect sizes for eﬃciency of all
treatments, globally, were 1.68 (95CI 1.25 to 2.12), 0.45 (0.26–0.64), and 0.76 (0.59–0.90), respectively. Except
usual lid hygiene for mites count, Children's Hospital of Eastern Ontario ointment (CHEO) for both eradication
rate and symptoms, and CHEO, 2% metronidazole ointment, and systemic metronidazole for eradication rate, all
treatments were eﬃcient. Stratiﬁed meta-analysis did not show signiﬁcant diﬀerences between local and sys-
temic treatments (1.22, 0.83 to 1.60 vs 2.24, 1.30 to 3.18 for mites count; 0.37, 0.21 to 0.54 vs 0.56, 0.06 to 0.99
for eradication rate; and 0.77, 0.58 to 0.92 vs 0.67, 0.25 to 0.98 for symptoms improvement).
Conclusion: We reported the eﬃciency of the diﬀerent treatments of Demodex blepharitis. Because of less sys-
temic side eﬀects, local treatments seem promising molecules in the treatment of Demodex blepharitis.
Introduction
Blepharitis is a common eye inﬂammation aﬀecting eyelash, eyelid
and ocular surface with sometimes corneal resounding. Among many
causes, Demodex mites are found since the 19th century with princep
observation by Henle and Simon [1,2]. There are two host-speciﬁc
obligate mites' species found in human being's hair follicles, sebaceous
glands (Zeiss ‘glands) and eyelid glands (Meibum's glands) causing
anterior and posterior blepharitis: Demodex folicularum and Demodex
brevis. Typically, Demodex folicularum found in clusters around the
eyelash and eyelid skin whereas Demodex brevis resided alone in the
deep of sebaceous and Meibomian glands [3–5]. Mites' presence may
cause inﬂammatory process in some eyelid tissues, however the pa-
thogenesis' role of Demodex in inﬂammatory process of blepharitis is
discussed. Demodex would be the vector for number of bacterial and
mycotic pathogens, resulting in an immunological response at the
eyelid margins, with redness, itching and burning sensations [6–8].
Diagnosis of Demodex blepharitis is classically obtained by para-
sitologist with skin or follicles biopsies [1–6,8,9] or more recently by
confocal microscopy [10,11]. Cylindrical dandruﬀ at the base of eye-
lash is considered as pathognomonic of Demodex infestation [5,12,13].
This physiological lack of knowledge and saprophyte presence of
Demodex in healthy eyes have an impact on therapeutics with very few
studies in international scientiﬁc literature. During long years, usual lid
hygiene has been used to treat this kind of resistant blepharitis, some-
times with sulphuric ointment [1], yellow mercuric ointment
[1,4,9,14], pilocarpine gel [15,16] or locals’ antibiotics [17] without
proof of eﬃcacy. Anthelminthics, with systemic side eﬀects, have been
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used empirically these last years [18–21]. New local therapy based on
tea tree oil (TTO) and terpinen-4-ol (T4O) have been tested recently
[18,21–32], opening a new therapeutic ﬁeld. To our knowledge, there
are no synthesis of literature comparing Demodex treatments. To allow
a future consensus or new treatment elaboration is of major interest.
Therefore, we aimed to compute a systematic review and meta-
analysis to compare all eﬃcacy of Demodex blepharitis treatments.
More speciﬁcally, we aimed assess the comparative eﬃciency of local
and systemic treatments and to evaluate inﬂuencing parameters in
therapeutic eﬃcacy.
Methods
Literature search
We have searched all articles in PubMed, The Cochrane Library,
Central, Embase, ClinicalTrial.gov, Google Scholar and ScienceDirect
databases from February 2018 to August 2018 with following key-
words: (blepharitis OR blepharitides) AND (drug* OR pharmacotherapy
OR therap* OR treat* OR administration OR patient* OR outcome* OR
eﬃcacy OR eﬀective* OR clinical OR management OR compliance OR
adherence). We limited our search to articles written in English, French,
or Spanish. No minimal sample size was applied. To be included, arti-
cles needed to evaluate a therapy concerning Demodex blepharitis
proved by parasitological examination or confocal microscopy or cy-
lindrical dandruﬀ. We imposed no limitation of regional origin or
control group nature. In addition, references list of all publications was
manually searched to identify any other ones not found with electronic
search. The search strategy is presented in Fig. 1. One author conducted
all literature searches (Valentin Navel) and collated the abstracts. Two
authors (Valentin Navel and Cédric Benoist d’Azy) separately reviewed
the abstracts and based on the selection criteria, decided the suitability
of the articles for inclusion. A third author (Frédéric Dutheil) was asked
to review the articles where consensus on suitability was debated. Fi-
nally, all authors reviewed eligible articles.
Quality of assessment
Although not created for that, the “Strengthening the Reporting of
Observational studies in Epidemiology” (STROBE) criteria may be in-
appropriately used as an assessment tool to judge study quality, as well
as the CONSORT guidelines for randomized clinical trials. STROBE and
CONSORT are checklists of 22 and 30 items, respectively. We attributed
one point per items, then converted into percentage to give a quality
score for each included study [33–36].
We also used the SIGN criteria to also judge observational studies
and randomized clinical trials, with the dedicated evaluation grids.
SIGN Cohort Studies and SIGN Controlled Trials statements are a
checklist of 18 and 14 items, respectively. We gave a general quality
score for each include study based on the main causes of bias evaluated
in section 1 of both checklists through 4 possibilities of answers (yes,
no, can't say or not applicable) [37].
Statistical considerations
Statistical analyses were performed using Stata (v12, StataCorp, US)
[38–44]. Parameters were reported as mean ± standard-deviation
(SD) or number (%) for continuous or categorical variables. Treatment
eﬃcacy was assessed using Hedges bias corrected eﬀect size (ES) of
parasite count evolution (before-after treatment) as primary outcome.
Parasite eradication rate and symptoms improvement rate were con-
sidered as secondary outcome. ES and 95% conﬁdence interval (CI)
were presented on forest plots, as a unitless measure of the eﬀects of
treatments for Demodex blepharitis on mites count, eradication rate,
and symptoms improvement. An ES centered at zero means the absence
of eﬃcacy, 0.2 a small eﬀect, 0.5 a moderate eﬀect, and 0.8 a large
eﬀect [45]. Funnel plots assessed the publication bias. I-squared (I2)
quantiﬁed heterogeneity between studies, graded as low (< 25%),
moderate (25–50%) or high (> 50%). All statistical tests were two-
sided; signiﬁcance was set for p < 0.05. When sample size was suﬃ-
cient, meta-regressions (expressed as regression coeﬃcient and 95% CI)
were proposed to study relationships between parameters variation and
clinically relevant parameters such as age, sex ratio and eyelash sam-
pling method.
Results
With the keywords described, an initial search produced 2796 ar-
ticles (Fig. 1). After removal of the duplicates and applying selection
criteria, we included 19 articles [14–16,18,18–32].
More details on study characteristics, quality of articles (Figs. 2 and
3), method of Demodex identiﬁcation, type of treatments, protocol for
each treatment, inclusion and exclusion criteria of each included study,
population, aims and outcomes of included studies are described in
Appendix 1.
Meta-analyses and meta-regressions
Mites count: Fifteen studies were included [14,16,19–25,27–32]
with an overall ES of 1.68 (95CI 1.25 to 2.12) for all treatments. Except
usual lid hygiene, all treatments decreased mites count (Fig. 4 and
Fig. 5, and Appendix 2). Stratiﬁed meta-analysis did not show sig-
niﬁcant diﬀerences between local (1.22, 0.83 to 1.60) and systemic
(2.24, 1.30 to 3.18) treatments (Figs. 6 and 7), or between eyelash
sampling with (1.31, 0.80 to 1.81) or without (1.49, 1.02 to 1.96) cy-
lindrical dandruﬀ (Fig. 6, and Appendix 5). There were also no sig-
niﬁcant inﬂuences of age and gender (Fig. 6). Meta-regressions com-
paring treatments eﬃcacy were not feasible due to limited number of
data (most treatments were only reported in one study), despite stra-
tiﬁed meta-analysis on each treatment demonstrated ES greater than
2.5 for oral metronidazole + oral ivermectin (3.66, 95CI 2.84 to 4.48),
and 5%TTO (2.66, 2.17 to 3.15); greater than 1 for ivermectin alone
(1.80, 1.10 to 2.50), 50%TTO (1.74, 0.81 to 2.67), pilocarpine gel
(1.72, 0.71 to 2.73), and T4O (1.36, 0.60 to 2.11); and greater than 0.8
for Cilclar 1.9% + oxide mercuric ointment + ether application (0.81,
0.26 to 1.34), CHEO (0.53, 0.12 to 0.94) and OLSP (0.95, 0.53 to 1.37)
(Figs. 4 and 5, and Appendix 2).
Eradication rate of mites: Fourteen studies were included
[14,15,18,20–24,27,29–32,46] with an overall ES of 0.45 (0.26–0.64)
for all treatments. Except CHEO, 2% metronidazole ointment, andFig. 1. Search strategy.
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systemic metronidazole, all treatments improved eradication rate
(Figs. 4 and 5, and Appendix 3). Stratiﬁed meta-analysis did not show
signiﬁcant diﬀerences between local (0.37, 0.21 to 0.54) and systemic
(0.56, 0.06 to 0.99) treatments (Figs. 6 and 7), or between eyelash
sampling with (0.30, 0.12 to 0.51) or without (0.46, 0.25 to 0.68) cy-
lindrical dandruﬀ (Fig. 6, and Appendix 5). As for mites count, there
were also no signiﬁcant inﬂuences of age and gender (Fig. 6), and meta-
regressions comparing treatments eﬃcacy were also not feasible due to
limited number of data (one study per treatment, mainly). However,
stratiﬁed meta-analysis on each treatment demonstrated ES greater
than 0.8 for systemic metronidazole + ivermectin (1.00, 0.80 to 1.00),
and pilocarpine gel (0.92, 0.81 to 0.97); greater than 0.5 for Cilclar
1.9% + oxide mercuric ointment + ether application (0.57, 0.33 to
0.59), 50%TTO (0.54, 0.25 to 0.82), and ivermectin (0.54, 0.01 to
Fig. 2. Methodological quality of included cohort articles using the SIGN model.
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1.00); and greater than 0.2 for Ocusoft lid scrub (0.46, 0.28 to 0.65),
5%TTO (0.43, 0.04 to 0.87), T4O (0.41, 0.23 to 0.61), and usual lid
hygiene (0.22, 0.02 to 0.53) (Figs. 4 and 5, and Appendix 3).
Symptoms improvement: Thirteen studies were included
[14–16,18,19,21–24,26,28,31,32,46] with an overall ES of 0.76
(0.59–0.90) for all treatments. Except CHEO, all treatments improved
symptoms (Figs. 4 and 5, and Appendix 4). Stratiﬁed meta-analysis did
not show signiﬁcant diﬀerences between local (0.77, 0.58 to 0.92) and
systemic (0.67, 0.25 to 0.98) treatments (Figs. 6 and 7), or between
eyelash sampling with (0.81, 0.37 to 1.00) or without (0.73, 0.55 to
0.89) cylindrical dandruﬀ (Fig. 6, and Appendix 5). As for mites count
and eradication rate, there were also no signiﬁcant inﬂuences of age
and gender (Fig. 6), and meta-regressions comparing treatments eﬃ-
cacy were also not feasible due to limited number of data (one study per
treatment, mainly). CHEO were less eﬃcient than usual lid hygiene
with a coeﬃcient of −1.02 (−1.33 to −0.71) (Fig. 6). However,
stratiﬁed meta-analysis on each treatment demonstrated ES greater
than 0.8 for T4O (1.00, 0.85 to 1.00), Ocusoft lid scrub (1.00, 0.86 to
1.00), 50% TTO (0.97, 0.86 to 1.00) and 5% TTO (0.81, 0.60 to 0.96);
greater than 0.5 for Cilclar 1.9% + oxide mercuric ointment + ether
application (0.79, 0.52 to 0.92), systemic ivermectin (0.78, 0.31 to
1.00), 4% pilocarpine gel (0.74, 0.60 to 0.84) and usual lid hygiene
Fig. 3. Summary bias risk of included cohort studies and controlled trials articles using the SIGN model.
Fig. 4. Meta-analysis on mite's count, eradication rate and symptoms improvement rate in each treatment protocol (95% CI: 95% Conﬁdence intervals).
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(0.54, 0.42 to 0.65); and greater than 0.2 for Naviblef (0.41, 0.26 to
0.57), 2% metronidazole ointment (0.20, 0.04 to 0.62) and systemic
metronidazole (0.20, 0.04 to 0.62) (Figs. 4 and 5, and Appendix 4).
Discussion
Our study is the ﬁrst systematic evaluation of treatments for
Demodex blepharitis. Physiopathology of this commensal parasite were
a hindrance to the development of various therapies. We reported the
eﬃciency of the diﬀerent treatments of Demodex blepharitis. More
interestingly, stratiﬁed meta-analysis did not show signiﬁcant diﬀer-
ences between local and systemic treatments. Because of less side ef-
fects, local treatments seem promising to manage Demodex blepharitis.
We did not demonstrate inﬂuence of sociodemographic in the eﬃcacy
of treatments.
Rational of study
Despite Demodex was ﬁrst identiﬁed 150 years ago, it only attracted
wider interest recently, over the last 10 years [1]. In fact, the relative
current ignorance of physiopathology is a drawback in therapeutics’
evaluations. Initially, Demodex was considered as a saprophyte parasite
normally colonising the eyelashes. Current consensus proposed to
consider as physiological a number of mites< 5 mites/cm2 for skin
lesions or< 3 mites at the root of each eyelash [4,20,47]. However,
mites outbreaks may play a role in the pathophysiology of the infection,
causing a local inﬂammatory reaction and a repercussion on the ocular
surface [1,5,8,9,13,48–50]. Therefore, several therapeutics were used
such as antiparasitic, antiseptics, or anti-inﬂammatory drugs. Our meta-
analysis was needed because most treatments were used without sound
proof of eﬃciency and without randomized controlled trials comparing
eﬃciency of treatments. We chose Demodex count as primary judge-
ment criteria because the presence of some mites may be considered as
normal and outbreaks pathological. Eradication rate was chosen as a
secondary judgement criteria to evaluate the in vivo killing eﬀect in
parallel of mites count decrease.
Interest molecules
Initially, usual lid hygiene has been used to treat resistant ble-
pharitis with sulphuric ointment [1], yellow mercuric ointment
[1,4,9,14] or pilocarpine gel [15,16]. Sulphuric ointment or yellow
mercury treatments were poorly supported and are now obsolete (last
publications are more than twenty years old) [2,5,13,51,52] whereas
Fig. 5. Meta-analysis on mite's count, eradication rate and symptoms improvement rate in each treatment protocol (95% CI: 95% Conﬁdence intervals).
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pilocarpine, a well-known molecule in glaucoma, showed interesting
results with gel form [15,16]. Its antiparasitic eﬀect may be based on
parasympathomimetic action resulting in paralysis of mites' respiration
and mobility [15,16]. Over the last three decades, anthelminthics, such
as ivermectin or metronidazole, were used empirically to treat De-
modex blepharitis, as an oﬀ-label drug prescription outside marketing
authorisation [18–21]. Ivermectin is an eﬀective orally administered
antiparasitic drug, known since several years. Whereas the acaricidal
eﬀect of metronidazole on the Demodex mite is unknown [20,53,54],
the parasitic killing eﬀect of ivermectin is well known, through a se-
lective activity against glutamate-gated chloride ion channels from the
peripheral nervous system of invertebrates. These last years, news lo-
cals' therapies based on TTO and T4O have been tested [18,21–32],
opening a new therapeutic ﬁeld. TTO is a natural substance extracted
from the leaves of the Melaleuca alternifolia, a plant of the Myrtaceae
family. This product was known for a long time by Australian in-
digenous concerning antiseptic properties [55,56]. Some studies con-
cerning TTO proved its antifungal, antibacterial, antiviral and anti-
parasitological eﬀects [57–61]. T4O is the most active ingredient of
TTO with concentration from 30 to 48% [56]. The results of TTO, T4O
and pilocarpine uses corroborated the results of in vitro killing eﬀect
[27]. To our knowledge, in most countries, no treatment based on TTO
or T4O are available to clinicians with marketing authorisation to treat
Demodex blepharitis. It would be interesting to evaluate these news
locals’ treatments in clinical trials to prove their eﬃcacy, and to con-
sider these molecules in therapeutic association.
Proposal of recommendations for the treatment of Demodex blepharitis
In our meta-analysis, all Demodex blepharitis included from in-
dividual studies were resistant to the ﬁrst-line treatment such as usual
lid hygiene and local antibiotics [14–16,18–32,46]. Thus, negative re-
sults of usual lid hygiene were expected. However, its mechanical ef-
fects have been proved and should at an early stage [17,62–64]. More
interestingly, we demonstrated that local and systemic treatments had
comparable eﬃciency (1.22, 0.83 to 1.60 vs 2.24, 1.30 to 3.18 for mites
count; 0.37, 0.21 to 0.54 vs 0.56, 0.06 to 0.99 for eradication rate; and
0.77, 0.58 to 0.92 vs 0.67, 0.25 to 0.98 for symptoms improvement). As
mentioned upper, Demodex mites are present in healthy eyelids so it
could be unnecessary to employ toxic or very eﬀective systemic treat-
ment. In included studies, clinical side eﬀects or hepatic toxicity were
not observed with systemic ivermectin or metronidazole [18,19,21].
However, hypersensitivity reaction is more common with systemic
treatments compared with local treatments. Serious reactions were
observed using ivermectin or metronidazole in other parasitic infections
such as Mazzotti reaction (tachycardia, hypotension, arthralgias, oe-
dema, and abdominal pain), Steven-Johnson and Lyell disease, fatal
encephalopathy, increased INR (International Normalized Ratio) with
Fig. 6. Meta-regressions about parameters of analyses (95% CI: 95% Conﬁdence intervals).
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hemorrhage, decrease in leukocyte count and anemia, hepatitis, ele-
vation of liver enzymes, and elevation of bilirubin. Ivermectin should
not be used during pregnancy since safety in pregnancy has not been
established [20,21,53,54]. In blepharitis Demodex, the sides eﬀects
with local uses of TTO, T4O or pilocarpine were rare and benign, such
as eyes irritations, redness eyelid, cutaneous eczema, itching or burning
sensations, but never systemic reactions [14,18,22–32,46]. Therefore,
considering that cylindrical dandruﬀs at the base of the eyelashes are
pathognomonic of Demodex blepharitis [5,13,27], and considering our
results, we propose to treat blepharitis with cylindrical dandruﬀs with
antiparasitic local ﬁrst-line treatment i.e. the association of TTO, T4O
or pilocarpine gel with usual lid hygiene once or twice daily during 1–3
months. In second-line or in severe cases, systemic treatment such as
ivermectin or metronidazole could be added, which may also decrease
recurrence – although not proved –, without severe side eﬀects reported
with systemic low dose in the treatment of Demodex blepharitis. Severe
cases refer to severe ocular repercussions such as keratitis, corneal
ulcer, severe itching with skins lesions, trichiasis, ectropion or en-
tropion with corneal lesions. Combination of both systemic and local
treatment may also be interesting in some putative facial extensive
Demodex outbreaks, such as rosacea [65–67].
Parameters inﬂuencing therapeutics
In epidemiological studies, the inﬂuence of socio-demographic
parameters on mites count was controversial. It was described a higher
prevalence of infestation in people with oily or mixed skin than with
dry or neutral skin [68–71], in humid-tropical climate [72], in im-
munocompromised patients [73–77], or in childhood malnutrition
[78]. Majority of studies concluded on an increase of mites count with
age [1,68,79,80], which may be explained by the decreasing activity of
the glands of Zeiss and the Meibomian glands with age [1,50,81].
However, in paediatric and teenage population, Demodex mites could
played a pathological role in recurrent chalazia, itching and redness
eyelid [28,30]. Diﬀerences between socio-demographic results could be
explained by variability of inclusion criteria. According to meta-re-
gression results, we did not ﬁnd signiﬁcant inﬂuences of age and gender
on mites count. Most of included studies were epidemiological and
recruited patients during conventional examination for refractive or
pre-surgical consultations. Many patients in these consultations may
have not complained of any symptoms whereas all patients in our study
were recruited because of chronic blepharitis (thus with a high prob-
ability of complaints).
Limitations
Our study had some limitations. Data collections and inclusion/
exclusion criteria were not identical within each studies, which may
have aﬀected our results, as well as heterogeneity due to diﬀerent study
designs – retrospective [18,22,24,30] or prospective studies, rando-
mized [15,20,25,29,31] or not [14,16,19,21,23,26–28,32,46]. Never-
theless, we combined a large number of patients and procedures to
permit a large overview, with sensitivity analyses (data not shown)
demonstrating similar results whatever study designs. Studies included
small samples and were exclusively monocenter, precluding general-
izability. Though, all continents and all ethnicities were included.
Moreover, we cover nearly 30 years of treatments of Demodex ble-
pharitis, with a wide range of therapeutics. However, the apparition of
new treatments precluded eﬃcacy analyses of same treatments over
time. All studies used conventional parasitological examination to
prove Demodex infestation. Despite diﬀerent number of eyelashes
sampled between included studies, and thus diﬀerence between studies
concerning mite's count before treatment, it did not inﬂuence our re-
sults because meta-analysis were on mites count changes. Other para-
meters evaluating eﬃcacy of treatments (e.g. tears quality [19,23],
speciﬁc questionnaires [19,29,31,32,46], infrared thermography [23])
were limited to few studies and diﬀering, precluding further analyses.
Fig. 7. Meta-analysis on mite's count, eradication rate and symptoms im-
provement rate in each treatment type (95% CI: 95% conﬁdence intervals).
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Conclusion
Except usual lid hygiene for mites count, CHEO for both eradication
rate and symptoms, and CHEO, 2% metronidazole ointment, and sys-
temic metronidazole for eradication rate, all treatments were eﬃcient.
TTO, T4O and pilocarpine gel are interesting molecules to elaborate
new eyewashes as ﬁrst-line local treatment of Demodex blepharitis. As
second-line treatment or in severe cases, systemic treatment as iver-
mectin or metronidazole could be used in association with local treat-
ments.
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Abbreviations and Acronyms
CHEO Children's Hospital of Eastern Ontario (cholestyramine 5% ointment)
CONSORT consolidated standards of reporting trials
ES eﬀect size;
INR International Normalized Ratio
OLSP Ocusoft lid scrub plus
SIGN Scottish Intercollegiate Guidelines Network
STROBE strengthening the reporting of observational studies in epidemiology
TTFW Dr Organic Tea Tree Face Wash
TTO tea tree oil
T4O terpinen-4-ol
US United State of America
95CI 95% conﬁdence interval
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Appendix 1
Details on study characteristics, quality of articles (Figs. 2 and 3), method of Demodex identiﬁcation, type of treatments, protocol for each
treatment, inclusion and exclusion criteria of each included study, population, aims and outcomes of included studies.
All articles were written in English except one in Spanish [14]. Included studies came from all continents: 6 from Asia [22,28–30,32,46], 3 from
Europe [14,18,31], 2 from South America [19,21], 6 from North America [15,16,23–25,27], 1 from Oceania [26] and 1 from Africa [20].
Quality of articles
Quality assessment of the 19 included studies was performed by STROBE and SIGN Cohort Studies criteria concerning observational studies,
CONSORT and SIGN Controlled Trials criteria concerning the randomized clinical trials. There were 14 observational studies
[14,16,18,19,21–24,26–28,30,32,46] and 5 randomized clinical trials [15,20,25,29,31]. Results of STROBE criteria varying from 63.6 [14] to 84.8%
[24], with a mean score of 75.1 ± 6.08. Results of CONSORT criteria varying from 72.9 [31] to 78.3% [20], with a mean score of 75.6 ± 2.70.
Overall, the studies performed the best in methods and introduction sections and worst in the discussion section. Results of SIGN Cohort Studies
criteria varying from 46.1 [24] to 92.3% [16] for Yes responses, with a mean score of 63.2 ± 10.9. Results of SIGN Controlled Trials criteria varying
from 55.5 [31] to 77.7% [20,25,29] for Yes responses, with a mean score of 71.1 ± 9.9 (Figs. 2 and 3).
Method of Demodex identiﬁcation
All studies used conventional parasitological examination to prove Demodex infestation in the base of eyelash [14–16,18,18–32]. Eyelashes were
sampled on all eyelids of both eyes for all included studies [14–16,18,18–32], with [22–25,27–29,32] or without [14–16,18–21,30,31,46] cylindrical
dandruﬀ. All studies using eyelashes with cylindrical dandruﬀ sampled two eyelashes per eyelid [22–25,27–29,32]. For studies sampling eyelashes
without cylindrical dandruﬀ, the number of eyelashes sampled per eyelid was three [21,46], ﬁve [14], or six [19]. When the eyelashes were sampled,
diﬀerent conservations’ solutions were used like glycerine or oil [20,46], saline solution [14,23,25,27,28,32], 2% methylcelluloses [19] or a mix of
20 μL saline solution + 20 μL 100% alcohol [22,24,29]. The examination unfolded by×50 and×100 magniﬁcation under light microscopy
[14,16,18,20,23,25,27,32,46] or× 100 and× 400 magniﬁcation [14,29] or slip lamp microscopy [22,24,26,28,30,31]. All studies have measured
and evaluated infestation in naked eye except one [46].
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Type of treatments
A total of 13 diﬀerent treatments were used: 6 studies used 50% TTO [22–24,27–29], 4 used 5% TTO in their treatment protocol [18,32,46], 3
used T4O eyewash [25,30,31], 2 used 4% pilocarpine gel [15,16], 6 used usual lid hygiene as principal treatment or control [15,16,25,27,29,31], 1
used Cilclar (1.5% boric acid) + 2% yellow mercury oxide ointment + ether application [14], 1 used 5% cholestyramine ointment called CHEO
(because it was developed initially by the Children's Hospital of Eastern Ontario) [32], 1 used OcuSoft Lid Scrub Plus (OLSP)(1,2-octanediol) [31], 1
used Naviblef (0.02% TTO) [18], 1 used 2% metronidazole ointment [18], 4 used systemic ivermectin [18–21], 1 used systemic metronidazole lonely
[20], and 1 used systemic metronidazole + ivermectin association [18]. In total, 4 studies used systemic treatments [18–21] and 16 studies used
local treatments [14–16,22–32,46], with one study using both systemic and local treatments [18].
Protocol for each treatment
50% TTO was used once a week during one month, in the hospital oﬃce, to scrub the lash roots for 3 sessions (10min interval) with a drop of
0.5% proparacaine because of eyes irritation and burning sensation of 50% TTO. In addition, at home, TTO shampoo and eyelid hygiene massage
were used twice daily during 1 month and then one daily thereafter [22–24,28,29].
5% TTO was used in two diﬀerent packaging: in eyelid gel [46] or in eyelid oil [18,26,28,32]. Patients applied TTO at home on the eyelash, twice
daily [18,32,46] or once after washing the face before sleeping [26], during 1 [18,32,46] or 3 months [26].
T4O, a major component of TTO, was used in two devices. Cliradex lid scrub device applied twice daily and Dr Organic Tea Tree Face Wash
(TTFW) containing 38% of T4O and applied twice daily, both during 3 months [25,30,31].
4% pilocarpine gel was spread once in the evening on the base of eyelashes, and removed in the morning, for 2 weeks [15,16].
Usual lid hygiene consisted of scrubbing eyelashes with saline solution, warm massage and soap solution once or twice daily [15,16,25,27,29].
No other treatments were applied except in one study where BlephEx™ microblepharoexfoliation device was used at home to provide debridement
and exfoliation at the lash margin [31].
Cilclar 1.9% (Novartis) and 2% oxide mercuric ointment were used twice and once daily at home, respectively, during 6 weeks, and ether was
applied once a week in hospital oﬃce [14].
CHEO ointment, containing 0.5% cholestyramine in petroleum jelly, was spread by lid massage for 4 weeks [32].
OcuSoft Lid Scrub Plus (OLSP) contained 1,2-octanediol. This substance which has been shown to have pediculicide potential was scrubbed on
the base of eyelashes in circular movements, once daily at home during 4 weeks [31].
Naviblef lid foam, containing 0.02% diluted TTO, was administered once in the morning to clean the lids, eye brow and face skin during 2
months [18].
2% metronidazole ointment was administered to the margins of the lower and upper lids once daily at bed time for 2 months [18].
Ivermectin was administered per os, 6 mg twice at a 14-day interval [18], 6 mg twice at a 14-day interval [21], or 200 μg/kg at a 7-day interval
[19,20].
Metronidazole was administered per os, 1 g per day during 10 days [18], or 750mg per days during two weeks in association with 200 μg/kg of
ivermectin at a 7-day interval [20].
Inclusion and exclusion criteria
All studies included patients diagnosed with chronic and treatment-resistant blepharitis, and with a proven parasitological ocular demodicosis
[14–16,18,18–32]. All studies included adults (> 18 years old) [14–16,18–27,29–32,46], except one study without age criteria [28]. Most studies
excluded the use of topical or systemic anti-inﬂammatory and antibacterial medications [16,19,20,23,25–27,29,31,32] and any kind of surgery prior
to inclusion [19,20,25,29,31].
Population
Sample size: We included a total of 934 patients, ranging from 5 [18] to 233 [26], for a total of 1741 eyes treated for Demodex blepharitis,
ranging from 10 [16,18] to 266 [26] in each included studies.
Gender: A total of 280 men and 521 women were included with a proportion of female ranging from 20 [20] to 80% [16]. Four studies did not
specify gender [15,18,27,31].
Age: All studies included adults [14–16,18–27,29–32,46], except one which included children [28]. Within each study, mean age ranged from
7.5 ± 2.5 [28] to 76.8 ± 5.0 years [16]. Age of patients for each study is reported in supplemental ﬁles (Appendix 2 to 5).
Aims and outcomes of included studies
All included studies aimed to evaluate eﬃcacy and safety of treatments for Demodex blepharitis, based on clinical outcomes [14–16,18,18–32].
All studies reported mites count before and after the diﬀerent treatments, eradication rate (no mites after treatment), and improvement of symptoms,
except four, six and six studies which did not report mites count [15,18,19,25,26,28]. eradication rate [16,19,25,26,28], and improvement of
symptoms [16,20,25,27,29,30], respectively.
V. Navel, et al. The Ocular Surface 17 (2019) 655–669
663
Appendix 2. . Meta-analysis on mite's count in each treatment protocol (95% CI: 95% conﬁdence intervals)
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Appendix 3. . Meta-analysis on eradication rate in each treatment protocol (95% CI: 95% conﬁdence intervals)
V. Navel, et al. The Ocular Surface 17 (2019) 655–669
665
Appendix 4. . Meta-analysis on symptoms improvement rate in each treatment protocol (95% CI: 95% conﬁdence intervals)
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Appendix 5. . Meta-analysis on mite's count, eradication rate and symptoms improvement rate in each eyelash sampling method (95% CI:
95% conﬁdence intervals)
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